Rituximab a chimeric monoclonal antibody targets the CD20

Rituximab a chimeric monoclonal antibody targets the CD20 molecule, leading to depletion of B-lymphocytes through antibody-dependent and complement-mediated cytotoxicity as well as by promotion of apoptotic mechanisms. Rituximab has been used in non-Hodgkin type B-cell lymphoma for over a decade,but is now being studied in a number of autoimmune conditions.It is proposed to be useful for Multiple sclerosis also.